StoxGlenmark Pharmaceuticals vs Fortis Healthcare: share price & financials comparison
NSE: GLENMARK vs FORTIS · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Glenmark Pharmaceuticals vs Fortis Healthcare at a glance
Glenmark Pharmaceuticals (GLENMARK) has a market capitalisation of ₹74,506 Cr, against ₹57,679 Cr for Fortis Healthcare (FORTIS). Over the past year Glenmark Pharmaceuticals has returned +43.1%, compared with -25.0% for Fortis Healthcare. On valuation, Fortis Healthcare trades at a lower P/E of 55.5 versus 84.1. Fortis Healthcare earns a higher return on equity (9.9% vs 7.9%). Glenmark Pharmaceuticals comes out ahead on financial health, momentum and technicals. Fortis Healthcare comes out ahead on size, valuation, profitability and growth. Across the scored metrics below, Glenmark Pharmaceuticals leads on 8 and Fortis Healthcare on 10. On StoxGud's 10-point checklist, Glenmark Pharmaceuticals scores 5/10 and Fortis Healthcare scores 4/10.
| Metric | Glenmark Pharmaceuticals | Fortis Healthcare |
|---|---|---|
| Size | ||
| Market cap | ₹74,506 Cr | ₹57,679 Cr |
| Revenue (latest FY) | ₹16,983 Cr | ₹9,128 Cr |
| Net profit (latest FY) | ₹0 Cr | ₹1,042 Cr |
| Valuation | ||
| P/E | 84.1 | 55.5 |
| P/B | 6.64 | 5.50 |
| Dividend yield | 0.19% | 0.13% |
| Profitability | ||
| Return on equity | 7.9% | 9.9% |
| Net profit margin | 5.6% | 10.5% |
| Operating margin | 20.3% | 22.2% |
| Growth | ||
| Revenue growth (YoY) | -31.3% | +17.3% |
| Net profit growth (YoY) | -100.0% | -3.0% |
| Revenue CAGR (multi-year) | +9.2% | +17.8% |
| Financial health | ||
| Debt to equity | 0.08 | 0.30 |
| Momentum | ||
| 1-month return | +16.5% | +1.0% |
| 1-year return | +43.1% | -25.0% |
| 3-year CAGR | +53.9% | +27.5% |
| 5-year CAGR | +37.6% | +22.6% |
| 10-year CAGR | +11.7% | +16.8% |
| Distance from 52W high | -1.4% | -25.1% |
| Technicals | ||
| RSI (14) | 85 | 62 |
| Price vs 200-day avg | +17.4% | -14.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Glenmark Pharmaceuticals | Fortis Healthcare |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 5/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Glenmark Pharmaceuticals or Fortis Healthcare?
Glenmark Pharmaceuticals has a market cap of ₹74,506 Cr and Fortis Healthcare has a market cap of ₹57,679 Cr as of 13 Nov 2026.
Which has a lower P/E, Glenmark Pharmaceuticals or Fortis Healthcare?
Fortis Healthcare has the lower P/E: Glenmark Pharmaceuticals trades at 84.1 and Fortis Healthcare at 55.5.
Which gave better returns in the last year, Glenmark Pharmaceuticals or Fortis Healthcare?
Glenmark Pharmaceuticals did better: Glenmark Pharmaceuticals returned +43.1% and Fortis Healthcare returned -25.0% over one year.
What is the difference between Glenmark Pharmaceuticals and Fortis Healthcare?
Both are NSE-listed companies in Healthcare. Glenmark Pharmaceuticals is about 1.3 times the size of Fortis Healthcare by market cap. In the latest financial year Glenmark Pharmaceuticals reported revenue of ₹16,983 Cr and Fortis Healthcare ₹9,128 Cr. Operating margin is 20.3% for Glenmark Pharmaceuticals and 22.2% for Fortis Healthcare. Debt to equity is 0.08 for Glenmark Pharmaceuticals and 0.30 for Fortis Healthcare.
Which is better, Glenmark Pharmaceuticals or Fortis Healthcare?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Glenmark Pharmaceuticals leads on 8 and Fortis Healthcare on 10. Glenmark Pharmaceuticals is ahead on financial health, momentum and technicals. Fortis Healthcare is ahead on size, valuation, profitability and growth. On StoxGud's rules-based checklist Glenmark Pharmaceuticals scores 5/10 and Fortis Healthcare scores 4/10. This is information, not advice: consult a SEBI-registered adviser before investing.